-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Aim ImmunoTech, a pharmaceutical company, recently announced that it has identified an effective in-body model at the Institute of Antivirals at Utah State University to test the dsRNA TLR3 excitant Ampligen.
results show that Ampligen can reduce the load of SARS-CoV-2 infectious virus by 90%.
Themas K., CEO of AIM ImmunoTech, said, "We are pleased with these results, which support ampligen as an in-nasal prophyracing therapy for COVID-19."
currently, there is a lack of proper animal models, so the company used THE-WA1/2020 strains of SARS-CoV-2 in 3D in-body models of normal human-source trachea/bronchial endosperm cells.
results show that Ampligen can reduce the load of SARS-CoV-2 infectious virus by 90%.
is believed to be a powerful positive regulator of human innate immunity.
brief review of AIM ImmunoTech's experimental history in SARS-like diseases, Ampligen showed significant antiviral activity in previous animal experiments with the SARS-CoV-1 virus.
Ampligen showed 100% protection survival benefits in the SARS-CoV-1 virus mouse model group.
.